The European Medicines Agency (EMA) has approved Boehringer Ingelheim's Bovela, a new vaccine for active immunization of cattle against the virus causing the severe cattle disease, bovine viral diarrhea (BVD). The launch of Bovela is planned for spring 2015.

Bovela is an important advance in safeguarding the health of cattle against one of the major cattle diseases with worldwide distribution. It reduces clinical signs and prevents the birth of so called persistently infected (PI) animals caused by transplacental infection. PI animals are considered the main reason why this disease is still perpetuated. Bovela is the first vaccine registered in the European Union containing both genotypes of the BVD virus (BVDV-1 and BVDV-2), according to the company.

Source: Boehringer Ingelheim